FDA ReviewedUpdated July 5, 2026

Ozempic Guide

Ozempic is the brand-name formulation of semaglutide FDA-approved for type 2 diabetes management, though it has become widely prescribed off-label for weight loss. It is available in doses of 0.5mg, 1mg, and 2mg weekly, and is manufactured by Novo Nordisk. Ozempic also carries an FDA indication to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

At a Glance

Generic NameSemaglutide
Brand NamesOzempic
FDA StatusFDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020). Weight loss is off-label use.[1]
Approval DateDecember 5, 2017[1]

How Ozempic Works

Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels. The same mechanism that controls blood glucose also suppresses appetite and slows gastric emptying, producing significant weight loss as a secondary effect. At 1–2mg doses, Ozempic delivers strong appetite suppression comparable to Wegovy's lower dose range.[2][3]

Dosing Schedule

Ozempic uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–40.25mg/week
Weeks 5+0.5mg/week
After 4+ weeks at 0.5mg1mg/week (if needed)
After 4+ weeks at 1mg2mg/week (max)

Side Effects

Common: nausea, vomiting, diarrhea, stomach pain, constipation. Injection site reactions are common in early weeks. Serious (rare): pancreatitis, diabetic retinopathy worsening, kidney injury, hypoglycemia when combined with sulfonylureas or insulin. Thyroid C-cell tumor risk noted in animal studies.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SUSTAIN-6 cardiovascular trial, Ozempic reduced the risk of major cardiovascular events by 26% vs. placebo (Marso et al. NEJM 2016, PMID 27633186). For weight loss specifically, the STEP-8 head-to-head trial (Rubino et al. JAMA 2022, PMID 34962517) used semaglutide 2.4 mg — the Wegovy dose, not the Ozempic 1 mg dose — and showed 15.8% weight loss vs 6.4% for liraglutide 3 mg. Ozempic itself is FDA-approved only for type 2 diabetes; Wegovy is the FDA-approved semaglutide for chronic weight management.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Ozempic

These telehealth providers offer access to semaglutide or compounded equivalents with online consultations and home delivery.

7.8/ 10
Verified partner

Gala

Best for: compounded GLP-1/GIP combo therapy on a yearly subscription with free shipping nationwide

★★★★☆3.9

Editorial score · methodology

$149/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Gala review →
7.4/ 10
Verified partner

RxSpan MD

Best for: shoppers wanting physician-led, pharmacy-transparent compounded GLP-1 with brand-name options

★★★★☆3.7

Editorial score · methodology

$249/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full RxSpan MD review →
7.4/ 10
Verified partner

Care Bare Rx

Best for: LGBTQ+-inclusive compounded GLP-1 telehealth

★★★★☆3.7

Editorial score · methodology

$199/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Care Bare Rx review →
7.4/ 10
Verified partner

Synergy Rx

Best for: broadest drug catalog in the Lion MD white-label cluster

★★★★☆3.7

Editorial score · methodology

$199/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Synergy Rx review →
8.5/ 10

Cost Plus Drugs

Best for: the cheapest transparent-pricing brand-name Ozempic channel

★★★★☆4.3

Editorial score · methodology

$279/mo
BrandSemaglutide
Get StartedRead full Cost Plus Drugs review →
7.9/ 10

Calibrate Health

Best for: year-long coaching wrap around insured branded GLP-1s

★★★★☆4

Editorial score · methodology

$25/mo
BrandSemaglutide
Get StartedRead full Calibrate Health review →

Cost Comparison

Ozempic cost & pricing →Savings & coupons →Dosing & titration →How to get it →

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded semaglutide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.

ProviderStarting Price
AM Rx$25/moVisit
Calibrate Health$25/moVisit
FitRx$25/moVisit
Roen Rx$25/moVisit
GOAL.MD$244/moVisit
Cost Plus Drugs$279/moVisit
Synergy Rx$499/moVisit
Care Bare Rx$705/moVisit
Vital Edge$705/moVisit
Modern Age$900/moVisit
Push Health$950/moVisit
Vaylen$997/moVisit
altRX$1149/moVisit
Levity$1199/moVisit
Healthicare$1200/moVisit
Gala$1299/moVisit
RxSpan MD$1299/moVisit
Effecty$1300/moVisit
Ark Health$1399/moVisit
Elevated Health$1399/moVisit
Eve$1399/moVisit
NuuVim$1498/moVisit
Concierge MD LA$1999/moVisit

Ozempic Head-to-Head Comparisons

Short-form verdict pages comparing Ozempic to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

Ozempic vs Mounjaro
SURPASS-2 head-to-head: Mounjaro 15mg dropped weight 11.2 kg vs Ozempic 1mg's 5.7 kg at 40 weeks. Ozempic wins on proven CV outcomes (SUSTAIN-6 MACE -26%).
Last verified 2026-05-27
Ozempic vs Rybelsus
Rybelsus is oral semaglutide (3/7/14 mg daily); Ozempic is injectable semaglutide (0.25-2 mg weekly). Same molecule — oral bioavailability ~1% means injection delivers more drug.
Last verified 2026-05-27
Ozempic vs Zepbound
Ozempic is labeled for type 2 diabetes; Zepbound for obesity and OSA. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7% at 72 weeks.
Last verified 2026-05-27
Ozempic vs Wegovy
Wegovy and Ozempic are the same molecule (semaglutide) from Novo Nordisk — Wegovy is FDA-labeled for obesity (max 2.4 mg); Ozempic for type 2 diabetes (max 2 mg).
Last verified 2026-05-27
Ozempic vs Foundayo
Ozempic is weekly semaglutide injection (T2D label, SUSTAIN-6 CV benefit). Foundayo is the first non-peptide oral GLP-1 (obesity label 2025, 11-12% TBWL in ATTAIN-1).
Last verified 2026-05-27
Ozempic vs Trulicity
SUSTAIN-7 head-to-head: Ozempic 1 mg cut A1C 1.8% and weight 6.5 kg vs Trulicity 1.5 mg's 1.4% and 3.0 kg. Trulicity wins on pediatric label and AWARD-7 kidney data.
Last verified 2026-05-28

See all drug-vs-drug verdicts.

Pivotal Ozempic Trial Walkthroughs

Endpoint-by-endpoint breakdowns of the trials that shaped the Ozempic label, with primary-source numbers and FAQs.

SUSTAIN-6
SUSTAIN-6 (Marso 2016, NEJM, PMID 27633186) is the cardiovascular-outcomes trial that earned semaglutide its FDA cardioprotection labeling for Ozempic. Across 3,297 adults with type 2 diabetes at high cardiovascular risk, weekly subcutaneous semaglutide (pooled 0.5 mg and 1.0 mg) reduced the three-point MACE composite by 26% versus placebo over a median 104 weeks. The MACE win was driven primarily by a 39% reduction in nonfatal stroke and a 26% directional reduction in nonfatal myocardial infarction; cardiovascular death and all-cause mortality were unchanged. A 22% reduction in new or worsening nephropathy stood alongside a notable safety signal: diabetic retinopathy complications were 76% more frequent on semaglutide, the trade-off that has shaped every semaglutide CVOT discussion since.
Phase 3 · N=3,297 · Last verified 2026-05-28
FLOW
FLOW (Perkovic 2024, NEJM, PMID 38785209) is the first GLP-1 receptor agonist trial designed and powered for a primary kidney outcome. The trial randomized 3,533 adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo and was halted early for efficacy after a planned interim analysis. Over a median 3.4 years of follow-up, semaglutide reduced the primary composite of major kidney-disease events and cardiovascular or kidney death by 24% versus placebo. The result drove the January 2025 FDA Ozempic label expansion for reducing the risk of kidney-disease progression and kidney failure in adults with type 2 diabetes and chronic kidney disease.
Phase 3b · N=3,533 · Last verified 2026-05-28
SUSTAIN-7
SUSTAIN-7 (Pratley 2018 Lancet Diabetes Endocrinol, PMID 29397376) is the first registrational head-to-head trial of two once-weekly GLP-1 receptor agonists. Novo Nordisk randomized 1,201 adults with type 2 diabetes inadequately controlled on metformin 1:1:1:1 to once-weekly subcutaneous semaglutide 0.5 mg, dulaglutide 0.75 mg, semaglutide 1.0 mg, or dulaglutide 1.5 mg for 40 weeks in an open-label design. At both the low-dose and high-dose comparisons, semaglutide cut HbA1c roughly 0.4 percentage points more than dulaglutide and reduced body weight by an additional 2.3 to 3.5 kg, with broadly similar gastrointestinal tolerability. The trial provided the regulatory and clinical basis for positioning semaglutide as the strongest A1C-reducing GLP-1 in the class.
Phase 3b · N=1,201 · Last verified 2026-05-28

Ozempic Patient Questions, Answered

Real patient questions about Ozempic pulled from named subreddits and answered with peer-reviewed trial data.

Top 10 Semaglutide Side-Effect Questions from Reddit, Answered
10 questions · 15 PubMed citations
Last verified 2026-05-27
Top 10 GLP-1 Insurance Coverage Questions from Reddit, Answered
10 questions · 12 PubMed citations
Last verified 2026-05-28
Top 10 GLP-1 Injection Technique Questions from Reddit, Answered with FDA Labels
10 questions · 11 PubMed citations
Last verified 2026-05-28

Ozempic Reference Cards

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Ozempic Missed Dose: 5-Day Rule Cheat Sheet (2026)
Ozempic is once-weekly semaglutide. The FDA label gives a clean rule for missed doses, anchored to a 5-day window from the originally scheduled injection day. This cheat sheet condenses that rule, the 48-hour spacing limit, restart protocol after a long gap, and the side-effect red flags onto one scannable page. DailyMed-sourced, current 2026.
4 min read · Last verified 2026-05-27
GLP-1 Injection Site Rotation: 8-Week Cheat Sheet (2026)
Wegovy, Ozempic, Zepbound, and Mounjaro all share the same three FDA-approved injection sites: abdomen, front of thigh, and back of upper arm. Reusing the same spot week after week causes lipohypertrophy — thickened fatty tissue that absorbs the drug erratically, leaving appetite suppression and weight-loss results inconsistent. This cheat sheet maps the approved sites, gives an 8-week rotation example, and lists the technique mistakes that send users back to the prescriber.
4 min read · Last verified 2026-05-28
GLP-1 to GLP-1 Switching (2026 Cheat Sheet)
Wegovy → Zepbound, Ozempic → Mounjaro, Saxenda → Wegovy — FDA labels do not address head-to-head switching directly. Starting-dose matrix, wait times between drugs, and red flags during the transition on one scannable page.
5 min read · Last verified 2026-05-28

Ranked PubMed Studies on Ozempic

Curated lists of the highest-impact peer-reviewed studies on Ozempic and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.

Top 10 PubMed Studies on Semaglutide for Weight Loss (2026)
Ten peer-reviewed semaglutide weight-loss studies anchored to the STEP program (STEP-1 to STEP-8, STEP-TEENS, STEP-HFpEF), the SELECT cardiovascular outcomes trial, and OASIS-1 high-dose oral. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27
Top 10 PubMed Studies on GLP-1 Cardiovascular Outcomes (2026)
Ten landmark cardiovascular outcomes trials that established GLP-1 receptor agonists as cardioprotective drugs beyond glycemic control. Covers MACE reduction in type 2 diabetes (LEADER, SUSTAIN-6, REWIND, HARMONY OUTCOMES, AMPLITUDE-O, PIONEER 6), the SELECT paradigm-shift in obesity without diabetes, kidney outcomes in FLOW, heart failure in STEP-HFpEF, and the foundational neutral ELIXA post-ACS trial. Each entry includes the PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27
Top 10 PubMed Studies on GLP-1 Receptor Agonists for Kidney Disease (2026)
Ten peer-reviewed studies that built the kidney-outcomes case for GLP-1 receptor agonists. FLOW (2024) is the only dedicated CKD pivotal trial and drove the January 2025 FDA kidney label for Ozempic. The other nine are renal-endpoint analyses from major cardiovascular outcomes trials (LEADER, REWIND, SUSTAIN-6, AMPLITUDE-O, ELIXA, SURPASS-4), the AWARD-7 dedicated moderate-to-severe CKD trial in dulaglutide, the FLOW SGLT2 interaction analysis, and a Lancet class-level meta-analysis. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27
Top 10 PubMed Studies on Retatrutide (Triple Agonist GLP-1/GIP/Glucagon) 2026
Ten peer-reviewed retatrutide studies tracing Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist from molecular discovery (Coskun 2022) through phase 1b (Urva 2022), the pivotal phase 2 obesity (Jastreboff 2023) and T2D (Rosenstock 2023) trials, MASLD (Sanyal 2024), body composition (Coskun 2025), kidney parameters (Heerspink 2025), the TRANSCEND-CKD phase 3 design (Heerspink 2025), gastric emptying mechanism (Urva 2023), and patient-reported eating attitudes (Kanu 2025). Phase 3 TRIUMPH trials are still pending publication as of May 2026. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27

Related Research on Ozempic

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Ozempic Legs: Loose Skin, Muscle Loss, and Leg Changes Explained
What 'Ozempic legs' actually are — subcutaneous fat loss, lean-mass reduction, and loose/saggy skin that make legs look thinner, older, hollow, or veiny after GLP-1 weight loss — who's most at risk, and how to prevent and manage it.
9 min read4 citations
First Signs Ozempic Is Working: Early Indicators a GLP-1 Is Taking Effect
How to know if Ozempic is working — the early signs that appear in the first 1–2 weeks (reduced food noise, earlier satiety, smaller portions, mild GI effects) and what meaningful weight loss actually looks like as the dose titrates up.
8 min read4 citations
Ozempic Muscle Cramps: Electrolytes, Dehydration, and What Helps
Muscle cramps on Ozempic are not a direct GLP-1 effect. The credible mechanism is secondary: reduced intake, GI fluid losses (vomiting, diarrhea), and rapid weight loss shift electrolytes. Evidence, honest framing, and what helps.
9 min read3 citations
Endoscopic Sleeve Gastroplasty (ESG): The Evidence vs GLP-1s and Surgery
Endoscopic sleeve gastroplasty (ESG) is an incisionless stomach-tightening procedure that produced 13.6% weight loss in the MERIT randomized trial - on par with semaglutide, below tirzepatide and surgery. The honest evidence on efficacy, safety, cost, reversibility, and how it compares to a GLP-1.
12 min read12 citations
Gastric Balloon vs GLP-1: Which Wins on Weight Loss, Durability, and Safety?
No head-to-head trial exists, but the shape is clear: a temporary 6-month gastric balloon delivers ~7-15% weight loss that partly reverses after removal, versus a GLP-1's ongoing ~15-21% sustained while taken. The balloon also carries FDA death reports a GLP-1 does not. For most people a GLP-1 or ESG is stronger; the balloon's niche is a short-term jump-start.
10 min read7 citations
ESG vs GLP-1 (Semaglutide and Tirzepatide): The Head-to-Head Evidence
A one-time incisionless procedure or a weekly injection for life? ESG produced ~13.6-16% weight loss vs ~14.9% for semaglutide and ~20.9% for tirzepatide, but no head-to-head trial exists. Efficacy, durability, cost over time, risk, and the combination that beats either alone.
12 min read6 citations

Frequently Asked Questions

Sources & methodology — as of July 2026
  1. 1.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SUSTAIN-6 Trial — Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso SP et al.)— New England Journal of Medicine.PMID: 27633186.
  3. 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.